

(b) the composition further comprises a second tumor associated polypeptide or an immunogenic fragment thereof which is a non-RUR-1 antisense cDNA-encoded tumor associated polypeptide or an immunogenic fragment thereof; or

(c) the cell further comprises a second tumor associated nucleic acid or polypeptide, which is a non-RUR-1 antisense cDNA nucleic acid or tumor associated polypeptide, or an immunogenic fragment thereof.

50.(amended) The vaccine composition of claim 47 [49], wherein the RUR-1 antisense cDNA-encoded tumor associated polypeptide or an immunogenic fragment thereof comprises the amino acid sequence of SEQ ID NO:3.

54.(amended) The vaccine composition of [any of] claim[s] 47[-53], further comprising an adjuvant or a pharmaceutically acceptable carrier.

61.(amended) The method of claim 60 wherein the agent is selected from the group consisting of a nucleic acid molecule comprising SEQ ID NO:1 or a unique fragment thereof; a cytolytic T lymphocyte; and an antibody or antibody fragment.

Remarks

Applicants have amended certain claims to eliminate multiple dependencies and/or clarify claim language. Subject matter added to the claims is supported in the claims as filed and in the specification. No new matter has been added.

Respectfully submitted,



John R. Van Amsterdam
Reg. No. 40,212
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210
Tel: (617) 720-3500

Attorney's Docket No. L0461/7099
Dated: November 2, 2000
X11/13/00